Answers are grounded in this paper and cite their sources.
Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.
No takes yet. Share an insight, caveat, or question.
Rolland et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: